ClinicalTrials.gg
CompletedNCT03657784Updated Oct 22, 2019

Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function

A Phase 1 interventional study of P03277 in Renal Insufficiency and Healthy Volunteers, sponsored by Guerbet. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Guerbet · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Oct 2017, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, non-randomized, successive cohorts design, multicenter, single dose phase I study.

The primary objectives are:

  • to evaluate the pharmacokinetics (plasma and urine) profile of P03277 following single intravenous injection (0.1 mmol/kg body weight) in patients with mild to severe renal impairment and in healthy volunteers with normal renal function used as reference.
  • to assess dialysability of P03277 following a single intravenous injection (0.1 mmol/kg body weight) in patients with end stage renal disease requiring hemodialysis.
Read the detailed description

A full range design including the different degrees of renal impairment and healthy volunteers used as reference has been chosen.

Enrolment will be successive starting with both healthy volunteers (cohort 1) and patients with mild renal impairment (cohort 2), then patients with moderate renal impairment (cohort 3), then patients with severe renal impairment (cohort 4) to end with patients with end stage renal disease (cohort 5). Pharmacokinetics and safety profiles following the confinement period will be reviewed per each successive cohort by a Data Monitoring Committee before starting recruitment of patients in the next cohort. Cohorts 1 and 2 will be recruited in parallel and Data Monitoring Committee review will start after the completion of these first two cohorts.

02

Conditions studied

  • Renal Insufficiency
  • Healthy Volunteers

Browse trials for

03

In context

Renal Insufficiency

1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

This study's enrollment of 40 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

For all subjects:

  • Subject being 18 years or older, able and willing to participate in the trial
  • Subject in good enough health status as determined by investigator according to medical history, physical examination, vital signs, 12 lead and laboratory tests at screening and inclusion

For healthy volunteers / cohort 1:

Healthy volunteer with stable normal renal function defined with an absolute value of ≥ 90 mL/min based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements

For patients with renal impairment / cohorts 2 to 5:

  • Cohort 2: patient with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements
  • Cohort 3: patient with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements
  • Cohort 4: patient with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements
  • Cohort 5: patient with end-stage renal failure who requires 3 hemodialysis sessions per week
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.

    Drug: P03277

  • Experimental
    Cohort 2

    P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.

    Drug: P03277

  • Experimental
    Cohort 3

    P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.

    Drug: P03277

  • Experimental
    Cohort 4

    P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.

    Drug: P03277

  • Experimental
    Cohort 5

    P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.

    Drug: P03277

Interventions

  • DrugP03277

    Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second

    Also known as: gadopiclenol

06

What researchers measure

Primary outcomes

  1. AUC

    AUC: area under the plasma concentration curve. Blood samples will be collected.

    Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)

  2. Cmax

    Cmax: peak concentration. Blood samples will be collected.

    Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)

  3. t1/2

    t1/2: terminal half-life. Blood samples will be collected.

    Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)

  4. CLT

    CLT: total clearance. Blood samples will be collected.

    Time frame: Prior to P03277 administration and at 2, 5, 10, 20, 30, 45 minutes and at 1, 2, 4, 6, 8, 12, 24 hours after administration for all cohorts. Additionally, after P03277 administration at 48 hours (cohorts 2-3-4), 72 hours (cohort 3) and 96 hours (cohort 4)

  5. Ae

    Ae: amount excreted. Urine samples will be collected.

    Time frame: Prior to P03277 administration and during the intervals 0-6, 6-24, 24-48 hours for all cohorts + during 48-72 and 72-96 hours intervals for cohorts 2-3-4, 96-120 hours interval for cohorts 3-4, 120-144 hours and 144-168 hours intervals for cohort 4

  6. Relative amount of eliminated P03277 in blood

    This outcome will be assessed for cohort 5 only. Venous blood samples will be collected at each session of hemodialysis.

    Time frame: Just before the start of the session and at 30, 90 minutes and 4 hours after the start of the session.

  7. Clearance of P03277

    This outcome will be assessed for cohort 5 only and at the first hemodialysis only. Arterial and venous blood samples will be collected.

    Time frame: Just before the start of the session and at 30 and 90 minutes after the start of the session.

  8. Dialysis clearance of P03277

    This outcome will be assessed for cohort 5 only. Venous blood and dialysate samples will be collected at each session of hemodialysis.

    Time frame: Just before the start of the session and at 30, 90 minutes and 4 hours after the start of the session.

Secondary outcomes

  1. P03277concentration in blood (long-term)

    Blood samples will be collected.

    Time frame: At 1, 3 and 6 months after P03277 administration

  2. P03277 concentration in urine (long-term)

    Urine samples will be collected.

    Time frame: At 1, 3 and 6 months after P03277 administration

07

Study locations

2 sites
  • Republican Clinical Hospital, Arensia EM Unit
    Chisinau, Moldova, Republic of
  • Arensia Phase I unit "Carol Davila" Nephrology Hospital
    Bucharest, Romania
08

References and documents

Publications

  • Bradu A, Penescu M, Pitrou C, Hao J, Bourrinet P. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function. Invest Radiol. 2021 Aug 1;56(8):486-493. doi: 10.1097/RLI.0000000000000764. PubMed 34197356 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Feb 2019, 15 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 5, 2018
StartActual
Oct 13, 2017
Primary completionActual
Feb 1, 2019
CompletionActual
Aug 23, 2019
Last update
Oct 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03657784
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Sep 5, 2018
Start date
Oct 13, 2017
Primary completion
Feb 1, 2019
Completion
Aug 23, 2019
Last update
Oct 22, 2019

Study contacts

Penescu Mircea, MD
principal investigator · Arensia Phase I unit "Carol Davila" Nephrology Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion